ECSP20050785A - Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents
Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)Info
- Publication number
- ECSP20050785A ECSP20050785A ECSENADI202050785A ECDI202050785A ECSP20050785A EC SP20050785 A ECSP20050785 A EC SP20050785A EC SENADI202050785 A ECSENADI202050785 A EC SENADI202050785A EC DI202050785 A ECDI202050785 A EC DI202050785A EC SP20050785 A ECSP20050785 A EC SP20050785A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyridin
- methyl
- ghrelin
- acyltransferase
- goat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general I, I en donde los grupos R1 y R2 se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18154824 | 2018-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20050785A true ECSP20050785A (es) | 2020-09-30 |
Family
ID=61157050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202050785A ECSP20050785A (es) | 2018-02-02 | 2020-08-24 | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
Country Status (21)
Country | Link |
---|---|
US (1) | US11254688B2 (es) |
EP (1) | EP3746451B1 (es) |
JP (1) | JP7015396B2 (es) |
KR (1) | KR20200116978A (es) |
CN (1) | CN111655700B (es) |
AU (1) | AU2019215707A1 (es) |
BR (1) | BR112020013082A2 (es) |
CA (1) | CA3087826A1 (es) |
CL (1) | CL2020001907A1 (es) |
CO (1) | CO2020009299A2 (es) |
CR (1) | CR20200332A (es) |
EA (1) | EA202091805A1 (es) |
EC (1) | ECSP20050785A (es) |
IL (1) | IL276136A (es) |
JO (1) | JOP20200190A1 (es) |
MA (1) | MA53075A (es) |
MX (1) | MX2020008053A (es) |
PE (1) | PE20210174A1 (es) |
PH (1) | PH12020551168A1 (es) |
SG (1) | SG11202006125VA (es) |
WO (1) | WO2019149657A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE054928T2 (hu) | 2016-08-05 | 2021-10-28 | Boehringer Ingelheim Int | Oxadiazolopiridin-származékok ghrelin O-aciltranszferáz (GOAT)-inhibitorokként törtenõ alkalmazásra |
WO2019149658A1 (en) * | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
CR20200332A (es) | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
JP2023526351A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法 |
EP4153600A1 (en) | 2020-05-22 | 2023-03-29 | Boehringer Ingelheim International GmbH | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
WO2023114472A1 (en) * | 2021-12-16 | 2023-06-22 | Icahn School Of Medicine At Mount Sinai | Heterocyclic compounds as 5ht2a biased agonists |
CN114426516B (zh) * | 2022-02-16 | 2022-11-04 | 安徽有吉医药科技有限公司 | 一种2-氨基-3-溴吡啶的制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
AU2007273057A1 (en) * | 2006-07-12 | 2008-01-17 | Merck Sharp & Dohme Corp. | Substituted pyrazoles as ghrelin receptor antagonists |
EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
EP3088397B1 (en) | 2007-04-11 | 2019-04-10 | Canbas Co. Ltd. | Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer |
CA2687611A1 (en) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
FR2933989B1 (fr) | 2008-07-16 | 2013-03-08 | Commissariat Energie Atomique | Procede de purification de microorganismes presents dans des echantillons liquides |
FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
EA020596B1 (ru) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
AU2008365555B2 (en) | 2008-12-15 | 2016-01-14 | Zealand Pharma A/S | Glucagon analogues |
JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
US20110078154A1 (en) | 2009-09-28 | 2011-03-31 | Accenture Global Services Gmbh | Recruitment screening tool |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
CN104144696A (zh) | 2011-12-23 | 2014-11-12 | 西兰制药公司 | 胰高血糖素类似物 |
WO2013125732A1 (en) * | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013192388A1 (en) * | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
US20170275249A1 (en) * | 2014-09-17 | 2017-09-28 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
JP6615896B2 (ja) | 2015-01-30 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロン合成酵素阻害剤 |
AR104673A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
AR104672A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
JP6957460B2 (ja) | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドCavion, Inc. | アンジェルマン症候群および関連する障害の処置方法 |
HUE054928T2 (hu) * | 2016-08-05 | 2021-10-28 | Boehringer Ingelheim Int | Oxadiazolopiridin-származékok ghrelin O-aciltranszferáz (GOAT)-inhibitorokként törtenõ alkalmazásra |
NZ750126A (en) * | 2016-08-11 | 2022-07-01 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
WO2018044663A1 (en) | 2016-08-29 | 2018-03-08 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
EP3746450B1 (en) | 2018-02-02 | 2022-03-16 | Boehringer Ingelheim International GmbH | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
CR20200332A (es) | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
WO2019149658A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
-
2019
- 2019-01-28 CR CR20200332A patent/CR20200332A/es unknown
- 2019-01-28 JO JOP/2020/0190A patent/JOP20200190A1/ar unknown
- 2019-01-28 US US16/966,483 patent/US11254688B2/en active Active
- 2019-01-28 BR BR112020013082-6A patent/BR112020013082A2/pt not_active Application Discontinuation
- 2019-01-28 JP JP2020541873A patent/JP7015396B2/ja active Active
- 2019-01-28 PE PE2020001161A patent/PE20210174A1/es unknown
- 2019-01-28 EA EA202091805A patent/EA202091805A1/ru unknown
- 2019-01-28 CN CN201980010416.2A patent/CN111655700B/zh active Active
- 2019-01-28 EP EP19702246.0A patent/EP3746451B1/en active Active
- 2019-01-28 AU AU2019215707A patent/AU2019215707A1/en not_active Abandoned
- 2019-01-28 SG SG11202006125VA patent/SG11202006125VA/en unknown
- 2019-01-28 CA CA3087826A patent/CA3087826A1/en not_active Abandoned
- 2019-01-28 MA MA053075A patent/MA53075A/fr unknown
- 2019-01-28 MX MX2020008053A patent/MX2020008053A/es unknown
- 2019-01-28 KR KR1020207025417A patent/KR20200116978A/ko unknown
- 2019-01-28 WO PCT/EP2019/051989 patent/WO2019149657A1/en unknown
-
2020
- 2020-07-19 IL IL276136A patent/IL276136A/en unknown
- 2020-07-21 CL CL2020001907A patent/CL2020001907A1/es unknown
- 2020-07-28 CO CONC2020/0009299A patent/CO2020009299A2/es unknown
- 2020-07-31 PH PH12020551168A patent/PH12020551168A1/en unknown
- 2020-08-24 EC ECSENADI202050785A patent/ECSP20050785A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US11254688B2 (en) | 2022-02-22 |
CL2020001907A1 (es) | 2020-10-30 |
CR20200332A (es) | 2020-09-03 |
CA3087826A1 (en) | 2019-08-08 |
CN111655700A (zh) | 2020-09-11 |
AU2019215707A1 (en) | 2020-07-09 |
JP7015396B2 (ja) | 2022-02-15 |
US20210053985A1 (en) | 2021-02-25 |
CO2020009299A2 (es) | 2020-08-21 |
MA53075A (fr) | 2021-05-12 |
CN111655700B (zh) | 2023-07-18 |
PH12020551168A1 (en) | 2021-05-31 |
BR112020013082A2 (pt) | 2020-12-01 |
EP3746451A1 (en) | 2020-12-09 |
MX2020008053A (es) | 2020-09-07 |
SG11202006125VA (en) | 2020-07-29 |
IL276136A (en) | 2020-09-30 |
EA202091805A1 (ru) | 2020-12-16 |
PE20210174A1 (es) | 2021-01-29 |
JOP20200190A1 (ar) | 2020-07-29 |
KR20200116978A (ko) | 2020-10-13 |
WO2019149657A1 (en) | 2019-08-08 |
EP3746451B1 (en) | 2023-07-12 |
JP2021512113A (ja) | 2021-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20050785A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) | |
CO2020009177A2 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
ECSP20050791A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
CO2019000601A2 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CO2018011550A2 (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
ECSP14023238A (es) | Nuevos derivados de ácidos indaniloxidihidrobenzofuranilacéticos y sus usos como agonistas del receptor gpr40 | |
SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
UY35171A (es) | Derivados de ácidos indaniloxidihidrobenzofuranilacéticos como agonistas de la gpr40 | |
NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
BR112019006987A2 (pt) | inibidores de receptor de glicocorticoide | |
CU24482B1 (es) | Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
MX2020003862A (es) | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). | |
UY35668A (es) | Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
BR112017006998A2 (pt) | compostos de aminopurina substituídos, composições dos mesmos e métodos de tratamento com os mesmos | |
BR112017007011A2 (pt) | compostos de metil-piperidina úteis para inibir a prostaglandina e2 sintase-1 microssômica |